IMMUTEP Ltd business relationships
Companies named in IMMUTEP Ltd’s 20-F filed 2026-10-23, and public companies whose annual reports name IMMUTEP Ltd. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 51 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in IMMUTEP Ltd’s annual report 7
“Subsequent to 30 June 2026, Novartis gave notice terminating the out-license agreement relating to ieramilimab, effective 9 August 2026.” SEC filing
“Immutep received initial fees from LabCorp in fiscal year 2021 and may be eligible to receive further revenues from commercial milestones as the collaboration progresses under its 2020 License and Collaboration Agreement with LabCorp.” SEC filing
“In June 2024, Immutep entered into its third and most important collaboration with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) for the registrational Phase III trial in non-small cell lung cancer called TACTI-004.” SEC filing
“In August 2026, the exclusive license and collaboration agreement was terminated on notice from Novartis and the asset is in the process of being transferred back to Immutep.” SEC filing
“In November 2022, Immutep signed a new Clinical Trial Collaboration and Supply Agreement with Merck KGaA and Pfizer to conduct the INSIGHT-005 trial.” SEC filing
“In November 2022, Immutep signed a new Clinical Trial Collaboration and Supply Agreement with Merck KGaA and Pfizer to conduct the INSIGHT-005 trial.” SEC filing
“Exercising its right to terminate for convenience, GSK terminated the license and research collaboration agreement effective from May 30 2024.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.